关闭
 
读者在线:用户名 密码
首页 期刊简介 投稿须知 期刊目录 专家风采 编委会 特邀顾问 联系我们 移动出版
  1. 1
  2. 2
  3. 3
  4. 4
  5. 5



刊物信息

期刊名称:药物分析杂志
主管单位:中国科学技术协会
主办单位:中国药学会
承办:中国食品药品检定研究院
主编:金少鸿
地址:北京天坛西里2号
邮政编码:100050
电话:010-67012819,67058427
电子邮箱:ywfx@nifdc.org.cn
国际标准刊号:ISSN 0254-1793
国内统一刊号:CN 11-2224/R
邮发代号:2-237
 

访问统计
您是第  1 0 3 3 7 3 2 3 位浏览者
您当前的位置:首页 >> 正文

PEG化重组人促红素质量控制方法和标准研究

Study on methods and requirements for quality control of Pegylated Erythropoietin(PEG-EPO)

分类号:
出版年·卷·期(页码):2012,32 (4):0-0
DOI: 10.16155/j.0254-1793.2017.01.01
-----摘要:-------------------------------------------------------------------------------------------

目的: 建立PEG化重组人促红素质量控制方法和质量标准。 方法: 用正常小鼠网织红细胞计数法测定体内生物学活性,使用iCE毛细管等电聚焦电泳分析异构体,用离子色谱确定N-糖链指纹图谱,反相HPLC进行Lys-C蛋白内切酶酶切的肽图分析以及纯度测定。其余检测项目按2010年版中国药典三部方法进行。 结果: 建立的方法经过比较和对PEG化重组人促红素的检测,结果稳定可靠,重复性好,各指标符合《人用重组DNA制品质量控制技术指导原则》和2010年版中国药典三部的要求。 结论: 本研究建立了一套完善的PEG化重组人促红素质量控制体系。

-----英文摘要:---------------------------------------------------------------------------------------

Objective: To establish methods and requirements for the quality control of PEG-EPO. Methods: In vivo bioactivity of PEG-EPO was determined by the count of reticulocytes in normocythaemic mice.Isoforms were analyzed by cIEF.Oligosaccharide fingerprint profiling was determined by HPAEC.Purity and peptide mapping were analyzed by reverse HPLC system.Other routine tests were all carried out according to the Chinese pharmacopoeia(volume Ⅲ,2010 edition). Results: The requirements and methods for the quality control of PEG-EPO have been established.The results of all tests were reliable and reproducible,and complied with the Chinese pharmacopoeia and guidelines for the quality control of recombinant DNA products. Conclusion: The methods and requirements for PEG-EPO showed the characteristics of assuring the products safety and efficacy,which can be used for the quality control of PEG-EPO.

-----参考文献:---------------------------------------------------------------------------------------
[1] Eschbach JW,Egrie JC,Downing MR,et al.Correction of the anemia of end-stage renal disease with recombinant human erythropoietin.Results of a combined phase Ⅰand Ⅱ clinical trial.N Engl J Med,1987,316(2):73
[2] Abels RI.Use of recombinant human erythropoietin in the treatment of anemia in patients who have cancer.Semin Oncol,1992,19(3 Suppl 8):29
[3] ZHOU Yong(周勇),WANG Jun-zhi(王军志),HUANG Pei-tang(黄培堂),et al.Quality evaluation of recombinant human erythropoietin by optimized isoelectric focusing assay(优化等电聚焦电泳方法评价重组人红细胞生成素质量).Chin J Biochem Pharm(中国生化药物杂志),2007,28(6):397
[4] ChP(中国药典).2010.Vol Ⅲ(三部):Appendix(附录):16,23,71,95
[5] TU Chun-yan(屠春燕),GU Wei(顾薇),PAN Zi-hao(潘自皓),et al.Improvement of the separating method for rhEPO by capillary zone electrophoresis(毛细管区带电泳分离重组人红细胞生成素方法的改进).Chin J Pharm Anal(药物分析杂志),2007,27(4):552
[6] ZHANG Xue-yan(张雪艳),CHEN Zhi-yong(陈智勇),WANG Qian-chuan(王黔川).Dye mPEG2-COOH in PEG-EPO with iodine reagents(PEG-EPO中残余聚乙二醇的碘染色法).Chin J Pharm Anal(药物分析杂志),2006,26(1):82

欢迎阅读《药物分析杂志》!您是该文第 2096位读者!

药物分析杂志 © 2009
地址:北京天坛西里2号 邮政编码:100050; 电子邮件:ywfx@nicpbp.org.cn